One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1016/j.jval.2022.04.435
Copy DOI
Export
Save
Share
Cite Journal: Value in Health |  Publication Date: Jun 25, 2022 |
 License type: publisher-specific-oa |
To estimate, from a US payer perspective, the cost-utility of adjuvant treatment of UC after radical resection with nivolumab versus observation using data with 11 months’ minimum follow-up from the Phase 3 CheckMate-274 trial and survival estimates from the published literature.
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
